Sign in
Not yet taking people in LatviaPhase 1

Tests TQS-168 safety in people with amyotrophic lateral sclerosis

Tests the drug TQS-168 in adults with amyotrophic lateral sclerosis, a nerve disease.

Key facts

Who runs it
Tranquis Therapeutics Inc.
Where
Riga, LatviaSee the site
Trial code
Registry title
A PHASE 1B, MULTICENTER, RANDOMIZED, PLACEBO- CONTROLLED, DOUBLE-BLIND STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND BIOLOGICAL ACTIVITY OF TQS-168 IN SUBJECTS WITH AMYOTROPHIC LATERAL SCLEROSIS
Status
Not yet recruiting
Phase
Phase 1
People taking part
16 people, planned
Started
1 Sept 2023
Planned end
31 Jul 2024
Type of study
Interventional
Record updated
11 October 2023

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with amyotrophic lateral sclerosis (ALS). It tests the safety and biological activity of TQS-168 compared with a placebo.

Age
18 years or older
Sex
Men and women can join

Where in Latvia

  • Pauls Stradins Clinical University HospitalRiga, LatviaNot yet recruiting

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).
Plain-language title
Tests TQS-168 safety in people with amyotrophic lateral sclerosisGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 9 November 2026.
Record updated
11 October 2023